JAMA : the journal of the American Medical Association
-
Randomized Controlled Trial Multicenter Study
Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.
Human infections with avian influenza A/H7N9 have resulted in high morbidity and mortality in China. ⋯ Point-of-use mixing and administration of 2 doses of H7N9 vaccine at the lowest tested antigen dose with MF59 adjuvant produced seroconversion in 59% of participants. Although these findings indicate potential value in this approach, the study is limited by the absence of antibody data beyond 42 days and the absence of clinical outcomes.